Loading stock…

The Cigna Group (CI) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

The Cigna Group

CIMarket cap $74BPrice $278.5

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Services

The Cigna Group provides health insurance and pharmacy benefits to 190 million people worldwide. Their pharmacy benefit manager, Express Scripts, fills one in four prescriptions in America, making them a pharmaceutical middleman powerhouse.

In Bastion Portfolios?

52W Return-6%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+15%8

Revenue Forecast

Rev CAGR (1y)+4%4

Rev CAGR (3y)+5%4

Rev CAGR (5y)+5%5

Earnings Forecast

EPS Growth Y+1+37%9

EPS Growth Y+2+7%6

EPS Growth Y+3+7%6

Quality

Margins

EBIT Margin4%2

Net Income Margin2%3

Free Cash Flow Margin3%3

Debt

Net Debt/EBITDA1.94

Efficiency

ROE15%7

ROA5%6

Earnings Stability55

GEAR+AVERAGE66

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)99

P/E Ratio (Forward 3y)89

P/BV1.77

EV Multiples

EV/EBITDA Fwd69

EV/EBIT Fwd89

Yield

Free Cash Flow Yield12.4%10

Dividend Yield2.2%6

Momentum

Short term

1 month return+1%8

3 month return-3%5

YTD return+3%5

Mid term

Price vs 52wHigh91%9

1 year return-7%4

Long term

3 year return+2%3

5 year return+49%6

Risk Shield

Price Risk

Beta0.29

Volatility33%6

Free Cash Flow

Free Cash Flow Margin3%3

Free Cash Flow Yield12.4%10

Quality

ROCE11%6

Earnings Stability55

Net Debt/EBITDA1.94

02Growth

Is it actually growing, and how fast?

CIThe Cigna

Revenue FY25$275B

GROWTH RATING↗

AVERAGE45 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+15%8

Revenue, next 1Y+4%4

Revenue, next 3Y, CAGR+5%4

Revenue, next 5Y, CAGR+5%5

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+37%9

EPS growth, FY27E+7%6

EPS growth, FY28E+7%6

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 15%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Earnings are set to grow in step with sales (EPS about 7%/yr vs revenue 5%/yr).

WATCH

A mid-pack grower, ahead of 45% of companies worldwide.

Revenue is set to grow 5%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 15%/yr over the last 3 years; forecasts see it cooling to 5%/yr.

Over five years revenue is set to grow 5%/yr, about average versus companies worldwide.5/10

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE57 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+1%8

3-month return-3%5

YTD return+3%5

MID & LONG-TERM▾SCORE

% of 52-week high91%9

1-year return-7%4

3-year return+2%3

5-year return+49%6

MOMENTUM ASSESSMENT

STRENGTHS

It's down 7% over the past year, now 9% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+1%).

WATCH

Average long-term results. Multi-year returns are middling (+2.4% over three years and +49% over five), roughly average for the market.

Returns sit at the market level over three months (-3%) and so far this year (+3%).

WEAKNESSES

None flagged.

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up.

04Value

Are you paying a fair price for it?

Stop guessing on Cigna. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

CIThe Cigna

Revenue FY25$275B

GROWTH RATING↗

AVERAGE45 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+15%8

Revenue, next 1Y+4%4

Revenue, next 3Y, CAGR+5%4

Revenue, next 5Y, CAGR+5%5

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+37%9

EPS growth, FY27E+7%6

EPS growth, FY28E+7%6

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 15%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Earnings are set to grow in step with sales (EPS about 7%/yr vs revenue 5%/yr).

WATCH

A mid-pack grower, ahead of 45% of companies worldwide.

Revenue is set to grow 5%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 15%/yr over the last 3 years; forecasts see it cooling to 5%/yr.

Over five years revenue is set to grow 5%/yr, about average versus companies worldwide.5/10

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE57 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+1%8

3-month return-3%5

YTD return+3%5

MID & LONG-TERM▾SCORE

% of 52-week high91%9

1-year return-7%4

3-year return+2%3

5-year return+49%6

MOMENTUM ASSESSMENT

STRENGTHS

It's down 7% over the past year, now 9% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+1%).

WATCH

Average long-term results. Multi-year returns are middling (+2.4% over three years and +49% over five), roughly average for the market.

Returns sit at the market level over three months (-3%) and so far this year (+3%).

WEAKNESSES

None flagged.

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up.

04Value

Are you paying a fair price for it?

Stop guessing on Cigna. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community